financetom
Business
financetom
/
Business
/
MRPL expects Rs 100-150 crore per year benefit from Kochi- Mangaluru pipe commissioning, says MD
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
MRPL expects Rs 100-150 crore per year benefit from Kochi- Mangaluru pipe commissioning, says MD
Jan 6, 2021 2:08 AM

Mangalore Refinery and Petrochemicals (MRPL) is looking at Rs 100-150 crore per year benefit from the Kochi-Mangaluru pipe commissioning, said M Venkatesh, Managing Director of the company. The MRPL stock has been buzzing recently after the Prime Minister inaugurated the nearly 450 kilometer Kochi- Mangaluru pipeline.

“We are completely ready in terms of hydrogen generation also as a feedstock. The gas turbines in the refinery are under modification and we expect that to happen by the year-end,” said Venkatesh in an interview with CNBC-TV18.

On the debt front, he said, “We have significant debt in our books and do not think debt will reduce in FY22. We shouldn’t be adding much to the debt but it all depends on how the market recovers and globally how the COVID aspects are taken care.”

Watch the video for more

(Edited by : Ajay Vaishnav)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Connexi Expands Global Supply Chain Capabilities with Acquisition of Crown Agents Inspections Private Limited
Connexi Expands Global Supply Chain Capabilities with Acquisition of Crown Agents Inspections Private Limited
Sep 23, 2025
WASHINGTON and NEW DELHI, Sept. 23, 2025 /PRNewswire/ -- Connexi, Chemonics International's supply chain subsidiary, today announced the acquisition of Crown Agents Inspections Private Limited, or CA Inspections, a leading quality assurance and inspection services provider in India. The acquisition strengthens Connexi's ability to deliver end-to-end supply chain solutions, expanding its reach in Asia and enhancing its capacity for product...
Neurocrine Biosciences Says Ingrezza Shows Earlier Remission of Tardive Dyskinesia Symptoms
Neurocrine Biosciences Says Ingrezza Shows Earlier Remission of Tardive Dyskinesia Symptoms
Sep 23, 2025
09:29 AM EDT, 09/23/2025 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said Tuesday that a phase 4 open-label study confirmed robust rates of symptomatic remission of tardive dyskinesia with once-daily Ingrezza capsules. The analysis also showed sustained improvements in patient-reported outcomes among participants who achieved symptomatic remission, the company said. Shares of the company were down 1% in recent...
Midland Exploration Starts Follow Up Program On Its New Discovery Of Gold-Zinc-Silver Mineralization at Caniapisc Au Project
Midland Exploration Starts Follow Up Program On Its New Discovery Of Gold-Zinc-Silver Mineralization at Caniapisc Au Project
Sep 23, 2025
09:29 AM EDT, 09/23/2025 (MT Newswires) -- Midland Exploration ( MIDLF ) announced Tuesday the start of a follow-up exploration program on its new discovery of gold, zinc, and silver on its Caniapisc Au project, in the Eeyou Istchee James Bay and Caniapiscau regions, and also announced map designation of two new projects in the same area. A statement noted...
Solid Biosciences Signs Licensing Deal With Kinea Bio for AAV-SLB101 to Treat Muscular Dystrophy
Solid Biosciences Signs Licensing Deal With Kinea Bio for AAV-SLB101 to Treat Muscular Dystrophy
Sep 23, 2025
08:31 AM EDT, 09/23/2025 (MT Newswires) -- Solid Biosciences ( SLDB ) said Tuesday that it has signed a non-exclusive licensing and collaboration agreement with Kinea Bio to use Solid Biosciences' ( SLDB ) proprietary AAV-SLB101 to treat muscle tropism and reduced liver uptake. Under the terms of the deal, Solid has granted Kinea Bio a non-exclusive worldwide license to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved